国产亚洲欧美日韩俺去了,人妻无码久久精品,亚洲人成影院在线观看,亚洲AV永久无码精品表情包

瑞萊,ReLIA Diagnostics,  
瑞萊生物工程（深圳）有限公司是美國加州著(zhù)名的 ReLIA 生物科技公司在中國的獨資企業(yè)，于2001年在深圳市高新技術(shù)產(chǎn)業(yè)園區注冊成立，注冊資金440萬(wàn)美元，投資總額800多萬(wàn)美元。

公司主要從事高新生物技術(shù)產(chǎn)品的研發(fā)及產(chǎn)業(yè)化生產(chǎn),其自主開(kāi)發(fā)的ReLIA檢驗系統與21世紀世界醫學(xué)檢驗學(xué)的重要發(fā)展趨勢同步，具備“快速、簡(jiǎn)便、全血、定量檢測”等床邊即時(shí)檢驗技術(shù)（POCT）的各種優(yōu)點(diǎn)，是國內率先擁有多項國際自主知識產(chǎn)權的POCT技術(shù)體系。企業(yè)已獲得國家食品藥品監督管理局(SFDA)頒發(fā)的《藥品生產(chǎn)許可證》和《醫療器械生產(chǎn)許可證》等證書(shū)，相關(guān)診斷試劑產(chǎn)品和檢驗儀器均擁有產(chǎn)品注冊證書(shū)。

公司擁有國際一流的研發(fā)和生產(chǎn)基地,其10萬(wàn)級GMP標準潔凈廠(chǎng)房已獲得國家藥監局(SFDA)的GMP認證,生產(chǎn)和質(zhì)量管理體系完全按照藥品GMP、ISO13485以及歐盟CE-MARK標準執行。

Rutter 博士現為 ReLIA（瑞萊）生物科技公司的董事長(cháng)、美國高科技控股公司 Synergenics 的董事長(cháng)兼首席執行官，美國科學(xué)院院士、加州大學(xué)醫學(xué)院 (UCSF) 榮譽(yù)教授。 Rutter 博士曾創(chuàng )辦美國著(zhù)名的生物制藥企業(yè) Chiron 公司，并任該公司董事長(cháng)多年，同時(shí)還兼任國際大型制藥企業(yè)如諾華 Novartis 公司、默克 Merck 公司的董事會(huì )成員。

Rutter 博士在國際生物技術(shù)和重組基因工程領(lǐng)域做出過(guò)許多重大的貢獻。他領(lǐng)導的實(shí)驗室首次克隆了人類(lèi)胰島素基因、首次利用 DNA 重組技術(shù)研制出乙型肝炎疫苗，1987 年更是首先發(fā)現并克隆了丙型肝炎病毒HCV，為發(fā)展高靈敏度病毒檢測試劑、疫苗以及治療藥物奠定了良好的基礎，先后發(fā)表了 380 多篇學(xué)術(shù)論文。他曾任美國加州大學(xué)醫學(xué)院生物化學(xué)系主任多年，任內該系誕生過(guò)兩位諾貝爾醫學(xué)獎獲得者。

Our goal is to provide central lab quality diagnostic testing to medical caregivers wherever fast, on-the-spot blood tests can improve the quality of patient care. When multiple biomarkers together can provide better information than a single biomarker can, we provide low-cost multiplexed tests with instant decision-making information. Bringing timely, high quality diagnostic information to the point-of-care will enhance the patient-doctor discussion and personalize follow-up treatment. Our strategy is to offer cardiovascular, cerebrovascular, acute kidney injury, and infectious disease biomarker panels in customer-proximity and point-of-care locations throughout the world.

Founder

William J. Rutter, Founder

Dr. Bill Rutter is Chairman and founder of ReLIA. The company is located in San Francisco’s Mission Bay /UCSF biomedical complex. It is a privately held company, under the umbrella of Synergenics LLC.

Dr. Rutter is also Chairman and CEO of Synergenics, which provides an innovative approach to advancing medical innovation into profitable start-up companies in the life sciences industry. Synergenics provides member companies (e.g., Humabs, Ventria, Synco, Numera, Pathologica, BioE, Epitomics) with investment, shared laboratories, scientific and industry expertise, and experienced management and administrative services. Synergenics provides a collaborative environment for the exchange of ideas and technology, while protecting each company’s IP.

Dr. Rutter is a member of the National Academy of Sciences and American Academy of Arts and Sciences and he has received numerous awards for his contributions to science and the biotechnology industry. He is Herzstein Professor Emeritus of Biochemistry at the University of California, San Francisco (UCSF). He co-founded Chiron Corporation (NASD: CHIR, acquired in 2005 by Novartis) and served as its Executive Chairman. Since the acquisition, Novartis has continued to build upon Chiron’s leadership in molecular diagnostic and vaccines. He has served on the boards of Novartis and numerous public and private biotechnology companies.